18144-43-9

Basic information

• Product Name: ISOPROPYL 4-AMINOBENZOATE
• Synonyms: propan-2-yl 4-azanylbenzoate;OTAVA-BB BB0107930013;TIMTEC-BB SBB007108;ISOPROPYL 4-AMINOBENZOATE;AURORA 3482;ASISCHEM V90897;ART-CHEM-BB B019993;ISOPROPYL P-AMINOBENZOATE
• CAS NO: 18144-43-9
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.22
• Product Categories: Aromatic Esters
• Mol File: 18144-43-9.mol
• Article Data: 11

Chemical Properties

• Melting Point: 84 °C
• Boiling Point: 315.7 °C at 760 mmHg
• Flash Point: 168.2 °C
• Appearance: /
• Density: 1.099 g/cm³
• Vapor Pressure: 0.12mmHg at 25°C
• Refractive Index: 1.456
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 2.63±0.10(Predicted)
• CAS DataBase Reference: ISOPROPYL 4-AMINOBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ISOPROPYL 4-AMINOBENZOATE(18144-43-9)
• EPA Substance Registry System: ISOPROPYL 4-AMINOBENZOATE(18144-43-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39-37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 18144-43-9(Hazardous Substances Data)

Usage

Uses

Isopropyl 4-Aminobenzoate serves as a model drug in the correlations studies between HPLC retention parameters and percutaneous absorption. Also functions as an inhibitor or an alternative acceptor substrate in the enzymic acetylation of p-nitroaniline.

InChI:InChI=1/C10H17Cl/c1-2-3-4-5-6-7-8-9-10-11/h2,5-10H2,1H3

Upstream product

• 150-13-0 4-amino-benzoic acid 
• 75-26-3 isopropyl bromide 
• 619-50-1 4-nitrobenzoic acid methyl ester 
• 67-63-0 isopropyl alcohol 
• 99-77-4 ethyl 4-nitrobenzoate 
• 122-04-3 4-nitro-benzoyl chloride 
• 62-23-7 4-nitro-benzoic acid 
• 75-30-9 2-iodo-propane 
• 5798-75-4 Ethyl 4-bromobenzoate 
• 94-09-7 p-aminoethylbenzoate 
• 13756-40-6 isopropyl 4-nitrobenzoate 

Downstream Products

• 1247021-53-9 1-methylethyl 4-(2-bromo-3-ethoxy-3-oxopropyl)benzoate 
• 58055-31-5 4-(3,3-Dimethyl-ureido)-benzoic acid isopropyl ester 
• 58055-32-6 4-(3-Methyl-ureido)-benzoic acid isopropyl ester 
• 140135-19-9 4-((S)-6-Benzyloxycarbonylamino-2-{[4-(benzyloxycarbonylamino-methyl)-cyclohexanecarbonyl]-amino}-hexanoylamino)-benzoic acid isopropyl ester 
• 103891-58-3 4-{(S)-6-Amino-2-[(4-aminomethyl-cyclohexanecarbonyl)-amino]-hexanoylamino}-benzoic acid isopropyl ester 
• 89101-12-2 C₁₂H₁₂N₂O₄ 
• 89101-08-6 C₁₂H₁₄N₂O₅ 
• 103892-82-6 4-((S)-6-Benzyloxycarbonylamino-2-tert-butoxycarbonylamino-hexanoylamino)-benzoic acid isopropyl ester 
• 131293-34-0 C₂₅H₂₀N₂O₄ 
• 131293-94-2 C₂₆H₂₃NO₆ 
• 131293-55-5 C₂₅H₂₃NO₄ 
• 89101-05-3 4-(Carboxymethyl-amino)-benzoic acid isopropyl ester 
• 134949-38-5 isopropyl 2-aminobenzo[d]thiazole-6-carboxylate 
• 131293-45-3 C₂₄H₂₀N₂O₆ 

Relevant articles and documents

Metal-Free Reduction of Aromatic Nitro Compounds to Aromatic Amines with B2pin2 in Isopropanol

A metal-free reduction of aromatic nitro compounds to the corresponding amines has been achieved by a combination of B2pin2 and KOtBu in isopropanol. A series of nitro compounds containing various reducible functional groups were chemoselectively reduced in good to excellent yields.

EP2/4 AGONISTS

EP2/4 compounds having improved dual pharmacological activity are described. The uniqueness of using EP2/4 dual agonists resides in their ability to modify both uveoscleral outflow via the ciliary muscle and conventional outflow via trabecular meshwork and Schlemm's canal all in the same treatment paradigm. The compounds can be employed for the treatment of glaucoma and ocular hypertension. Formula (I).

Synthesis, structure-activity relationship, and p210bcr-abl protein tyrosine kinase activity of novel AG 957 analogs

A series of novel, sterically hindered lipophilic analogs of AG 957 was designed and synthesized as potential protein tyrosine kinase (PTK) inhibitors. The in vitro activity, in vivo anti-leukemia activity, and pharmacology of these PTK inhibitors were studied. Some aspects of the structure-activity relationship associated with the carboxylic acid, phenol ring, and linker modifications are discussed. We have demonstrated that the 1,4-hydroquinone moiety is essential for activity and that sterically hindered esters contribute to enhanced in vivo efficacy. Adaphostin (NSC 680410) has emerged as the improved compound with the maximum in vivo anti-leukemia hollow fiber activity, concordant with the original lead compound AG 957. Currently, adaphostin is undergoing preclinical toxicology studies.